Clinical Trial Update: Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing Anrotenib plus toripalimab versus toripalimab alone in advanced esophageal squamous cell carcinoma; results not yet disclosed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anrotenib (Anrotenib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN